"NeverTouch Direct and the sheathless fiber option further expands the physician's ability to tailor treatment to each individual patient, and avoid one-size-fits-all approaches that limit the physician's ability to exercise their clinical judgment," said
The NeverTouch Direct kit, expected to launch in summer 2012, is indicated for endovascular coagulation of the great saphenous vein in patients with superficial vein reflux, for the treatment of varicose veins and varicosities associated with superficial reflux of the great saphenous vein, and for the treatment of incompetence and reflux of superficial veins of the lower extremity.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding
CONTACT: Company Contact:Source:
AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com Investor Relations Contacts: EVC Group, Inc. Greg Gin/ Doug Sherk(646) 445-4801; (415) 652-9100 email@example.com; firstname.lastname@example.org Media Contact: EVC Group, Inc. Chris Gale(646) 201-5431 email@example.com
News Provided by Acquire Media